Phio Pharmaceuticals Reports First Quarter 2019 Financial Results and Corporate Highlights

Wednesday, May 15, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

- Expansion of Industry Partners With Glycostem Therapeutics BV Collaboration

PHIO PHARMACEUTICALS CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands)

(Unaudited)

March 31,

December 31,

2019

2018

ASSETS

Current assets:

Cash

$            12,746

$            14,879

Restricted cash

50

50

Prepaid expenses and other current assets

117

221

Total current assets

12,913

15,150

Right of use asset

592

Property and equipment, net

155

172

Other assets

18

Total assets

$            13,678

$            15,322

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable

$                 721

$                 550

Accrued expenses

703

1,194

Lease liability

92

Total current liabilities

1,516

1,744

Lease liability, net of current portion

500

Total liabilities

2,016

1,744

Total stockholders' equity

11,662

13,578

Total liabilities and stockholders' equity

$            13,678

$            15,322



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store